Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2026)

Kymera Therapeutics has reported Change in Account Payables over the past 8 years, most recently at $8.8 million for Q1 2026.

  • Quarterly Change in Account Payables rose 125.27% to $8.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Mar 2026, down 17.03% year-over-year, with the annual reading at -$2.0 million for FY2025, 543.0% down from the prior year.
  • Change in Account Payables was $8.8 million for Q1 2026 at Kymera Therapeutics, up from -$1.5 million in the prior quarter.
  • Over five years, Change in Account Payables peaked at $8.8 million in Q1 2026 and troughed at -$4.1 million in Q2 2025.
  • The 5-year median for Change in Account Payables is $31000.0 (2024), against an average of $519647.1.
  • The largest YoY upside for Change in Account Payables was 5122.67% in 2025 against a maximum downside of 13432.26% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$2.1 million in 2022, then skyrocketed by 174.03% to $1.5 million in 2023, then crashed by 132.98% to -$505000.0 in 2024, then tumbled by 195.25% to -$1.5 million in 2025, then surged by 691.82% to $8.8 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Change in Account Payables are $8.8 million (Q1 2026), -$1.5 million (Q4 2025), and -$267000.0 (Q3 2025).